Rapid Diagnostics Assays and Antivirals for Noroviruses

诺如病毒的快速诊断检测和抗病毒药物

基本信息

  • 批准号:
    8636973
  • 负责人:
  • 金额:
    $ 29.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
    至 2015-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY (See instructions): Human caliciviruses are among the most important causes of gastroenteritis. Despite the increasing awareness of these agents as a major cause of diarrheal illness, assays for the diagnosis of human calicivirus infection are not available to most clinical laboratories. There are also no effective antivirals available that can be used therapeutically or prophylactically for this infection. This project will focus on high throughput approaches to develop rapid diagnostic assays for the detection of human caliciviruses and high throughput assays to identify potentially effective antiviral agents. We hypothesize that the reagents and strategies developed in the previous project period to target shared epitopes can be optimized and used to develop broadly reactive diagnostic assays for these antigenically diverse viruses. In Specific Aim 1, we will further optimize broadly-reactive reagents that can be used to make diagnostic assays for human caliciviruses. Studies in this aim will optimize single chain (scFv) antibodies with a range of binding specificities and monoclonal antibodies that recognize conserved epitopes, both of which were developed and characterized in the previous funding period. In Specific Aim 2, we will develop broadly-reactive diagnostic assays for human caliciviruses. Rapid formats that will be useable in the field to detect human caliciviruses will be identified. High affinity, cross-reactive single chain and monoclonal antibodies characterized in specific aim 1 will be used in assays that require minimal sample preparation and yield a result in less than 30 minutes. Formats to be evaluated are those that have been used successfully for the detection of other human viruses and include solid-phase immunoassays, and latex agglutination assays. In Speciflc Aim 3, we propose to develop high throughput assays to screen agents for antiviral activity against human noroviruses. A high throughput screen for inhibitors ofthe viral protease will be used to identify inhibitor candidates from small molecule libraries. The results obtained from project 1 studies will lead to the availability of new assays for the diagnosis of these important enteric pathogens and the identification of antiviral agents with the potential to diminish the disease burden caused these agents.
项目总结(见说明): 人类杯状病毒是引起肠胃炎的最重要原因之一。尽管人们越来越意识到 在这些作为结肠炎疾病的主要原因的试剂中,用于诊断人杯状病毒感染的测定是 大多数临床实验室都没有。也没有有效的抗病毒药物可以使用 治疗或预防这种感染。该项目将侧重于高通量方法,以开发用于检测人类杯状病毒的快速诊断方法和高通量方法,以识别潜在有效的抗病毒剂。我们假设,在前一个项目期间开发的靶向共享表位的试剂和策略可以优化,并用于开发这些抗原多样性病毒的广泛反应性诊断检测。在具体目标1中,我们将进一步优化可用于人类杯状病毒诊断检测的广泛反应性试剂。这一目标的研究将优化具有一系列结合特异性的单链(scFv)抗体和识别保守表位的单克隆抗体,这两种抗体都是在上一个资助期开发和表征的。在具体目标2中,我们将开发针对人类杯状病毒的广泛反应性诊断检测。将确定可用于现场检测人类杯状病毒的快速格式。特异性目的1中表征的高亲和力、交叉反应性单链和单克隆抗体将用于需要最少样品制备并在不到30分钟内产生结果的测定。待评价的ELISA是那些已成功用于检测其他人类病毒的ELISA,包括固相免疫测定和乳胶凝集测定。在具体目标3中,我们建议开发高通量测定来筛选针对人诺如病毒的抗病毒活性剂。病毒蛋白酶抑制剂的高通量筛选将用于从小分子文库中鉴定抑制剂候选物。从项目1研究中获得的结果将导致用于诊断这些重要肠道病原体的新检测方法的可用性,并确定有可能减少这些药物引起的疾病负担的抗病毒剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert L. Atmar其他文献

アグリバイオ 2020年5月号
农业生物2020年5月号
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kosuke Murakami;Victoria R. Tenge;Umesh Karandikar;Sasirekha Ramani;Khalil Ettayebi;Xi-Lei Zeng;Sue E. Crawford;Kazuhiko Katayama;Robert L. Atmar;Mary K. Estes;古賀道明;山﨑 毅(分担執筆:村上耕介)
  • 通讯作者:
    山﨑 毅(分担執筆:村上耕介)
Norovirus replication, host interactions and vaccine advances
诺如病毒复制、宿主相互作用和疫苗进展
  • DOI:
    10.1038/s41579-024-01144-9
  • 发表时间:
    2025-01-17
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    B. V. Venkataram Prasad;Robert L. Atmar;Sasirekha Ramani;Timothy Palzkill;Yongcheng Song;Sue E. Crawford;Mary K. Estes
  • 通讯作者:
    Mary K. Estes
588 GII.3 HUMAN NOROVIRUS REQUIRES BILE ACID AND CERAMIDE FOR ENTRY AND INFECTION OF HUMAN INTESTINAL ENTEROIDS
  • DOI:
    10.1016/s0016-5085(20)30994-x
  • 发表时间:
    2020-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Victoria R. Tenge;Kosuke Murakami;Umesh C. Karandikar;Shih-Ching Lin;Sasirekha Ramani;Khalil Ettayebi;Sue E. Crawford;Xi-Lei Zeng;Frederick H. Neill;B. Vijayalakshmi Ayyar;Kazuhiko Katayama;David Y. Graham;Erhard Bieberich;Robert L. Atmar;Mary Estes
  • 通讯作者:
    Mary Estes
Complete genomic characterization of global pathogens respiratory syntical virus and human norovirus using probe based capture enrichment
使用基于探针的捕获富集技术对全球病原体呼吸道合胞病毒和人类诺如病毒进行全基因组表征
  • DOI:
    10.1038/s41598-025-03398-6
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Sravya V Bhamidipati;Anil Surathu;Hsu Chao;Daniel P. Agustinho;Qin Xiang;Kavya Kottapalli;Abirami Santhanam;Zeineen Momin;Kimberly Walker;Vipin K. Menon;George Weissenberger;Nathanael Emerick;Faria Mahjabeen;Qingchang Meng;Jianhong Hu;Richard Sucgang;David Henke;Fritz J. Sedlazeck;Ziad M. Khan;Ginger A. Metcalf;Vasanthi Avadhanula;Pedro A. Piedra;Sasirekha Ramani;Robert L. Atmar;Mary K. Estes;Joseph F. Petrosino;Richard A. Gibbs;Donna M. Muzny;Sara Cregeen Javornik;Harsha Doddapaneni
  • 通讯作者:
    Harsha Doddapaneni
Possible alternative: Mechanism of bile-requiring GII.3 human norovirus replication in human intestinal enteroids
可能的替代方案:需要胆汁的 GII.3 人诺如病毒在人肠内复制的机制
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kosuke Murakami;Victoria R. Tenge;Umesh Karandikar;Sasirekha Ramani;Khalil Ettayebi;Xi-Lei Zeng;Sue E. Crawford;Kazuhiko Katayama;Robert L. Atmar;Mary K. Estes.
  • 通讯作者:
    Mary K. Estes.

Robert L. Atmar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert L. Atmar', 18)}}的其他基金

Rapid Diagnostics Assays and Antivirals for Noroviruses
诺如病毒的快速诊断检测和抗病毒药物
  • 批准号:
    7774777
  • 财政年份:
    2010
  • 资助金额:
    $ 29.59万
  • 项目类别:
Pathogenesis and Antivirals for Noroviruses
诺如病毒的发病机制和抗病毒药物
  • 批准号:
    8855694
  • 财政年份:
    2004
  • 资助金额:
    $ 29.59万
  • 项目类别:
Pathogenesis and Antivirals for Noroviruses
诺如病毒的发病机制和抗病毒药物
  • 批准号:
    9292240
  • 财政年份:
    2004
  • 资助金额:
    $ 29.59万
  • 项目类别:
Pathogenesis & Antivirals for Noroviruses
发病
  • 批准号:
    10450706
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Pathogenesis & Antivirals for Noroviruses
发病
  • 批准号:
    10674957
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Research Training in Infection and Immunity
感染与免疫研究培训
  • 批准号:
    9038215
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Mechanisms of Norovirus Pathogenesis and Replication to Develop Therapeutics
诺如病毒发病机制和复制机制以开发治疗方法
  • 批准号:
    10674942
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Pathogenesis & Antivirals for Noroviruses
发病
  • 批准号:
    10226007
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Mechanisms of Norovirus Pathogenesis and Replication to Develop Therapeutics
诺如病毒发病机制和复制机制以开发治疗方法
  • 批准号:
    10450701
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:
Rapid Diagnostic Assays for Human Calciviruses
人类杯状病毒的快速诊断分析
  • 批准号:
    6747786
  • 财政年份:
    2003
  • 资助金额:
    $ 29.59万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了